natgillin/translations-raw huggingface dataset:
The side effects listed below were seen when MVASI was given together with chemotherapy. 
Neželene učinke, ki so navedeni spodaj, so opazili, ko so zdravilo MVASI dajali skupaj s kemoterapijo.
Do not use MVASI if: 
Zdravila MVASI ne smete prejemati:
Permanently discontinue MVASI in patients with tracheoesophageal (TE) fistula or any grade 4 fistula [US National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE v.3)]. 
Pri bolnikih s traheoezofagealno fistulo ali katero koli fistulo stopnje 4 [US National Cancer InstituteCommon Terminology Criteria for Adverse Events (NCI-CTCAE v.3)] zdravilo MVASI dokončno ukinemo.
Limited information is available on the continued use of bevacizumab in patients with other fistulae. 
Za nadaljevanje uporabe bevacizumaba pri bolnikih z drugimi fistulami so na voljo le omejeni podatki.
A total of 452 patients were randomised to receive either: 
Skupno 452 bolnic so randomizirali na prejemanje ene od naslednjih shem:
• you are allergic (hypersensitive) to bevacizumab or to any of the other ingredients of this medicine (listed in section 6). 
• če ste alergični (preobčutljivi) na bevacizumab ali katero koli drugo sestavino tega zdravila
• a negative effect on a woman's ability to have children (see the paragraphs below the list of side effects for further recommendations), 
• negativni učinek na zmožnost zanositve (za nadaljnje informacije glejte spodaj),
• PLD 40 mg/m2 as a 1 mg/min IV infusion on day 1 only every 4 weeks. 
PLD 40 mg/m2 kot intravenska infuzija s hitrostjo 1 mg/min samo 1. dan vsake 4 tedne.
• MVASI can increase the risk of bleeding or increase the risk of problems with wound healing after surgery. 
• zdravilo MVASI lahko poveča tveganje za krvavitve ali poveča tveganje za težave pri celjenju ran po operaciji.
In two clinical trials of metastatic renal cell carcinoma, microangiopathic haemolytic anaemia (MAHA) was reported in 7 of 19 patients treated with bevacizumab (10 mg/kg every two weeks) and sunitinib malate (50 mg daily) combination. 
V dveh kliničnih preskušanjih metastatskega karcinoma ledvičnih celic so poročali o mikroangiopatični hemolitični anemiji pri 7 od 19 bolnikov, ki so jih zdravili s kombinacijo bevacizumaba (10 mg/kg na vsaka dva tedna) in sunitinibijevega malata (50 mg na dan).
Efficacy results for trial E3200 
Rezultati učinkovitosti za preskušanje E3200
IgGs are known to cross the placenta, and bevacizumab is anticipated to inhibit angiogenesis in the foetus, and thus is suspected to cause serious birth defects when administered during pregnancy. 
Znano je, da IgG prehajajo skozi placento, zato predvidevamo, da lahko bevacizumab povzroči zavrtje angiogeneze pri plodu in tako domnevno povzroča resne okvare ploda, če ga jemljejo nosečnice.
Clinical benefit in NSCLC patients has been demonstrated with both 7.5 mg/kg and 15 mg/kg doses (see section 5.1). 
Klinična korist pri bolnikih z nedrobnoceličnim rakom pljuč je bila dokazana tako za odmerek 7,5 mg/kg telesne mase kot tudi za 15 mg/kg telesne mase (glejte poglavje 5.1).
In an exploratory retrospective analysis of data from 13 completed randomised trials in patients with various tumour types, 3 patients out of 91 (3.3%) with brain metastases experienced CNS bleeding (all grade 4) when treated with bevacizumab, compared to 1 case (grade 5) out of 96 patients (1%) that were not exposed to bevacizumab. 
V eksplorativni retrospektivni analizi podatkov iz 13 zaključenih randomiziranih kliničnih preskušanj pri bolnikih z različnimi vrstami tumorjev so 3 bolniki od 91 (3,3 %), ki so imeli zasevke v možganih, imeli krvavitev v osrednjem živčevju (vsi stopnje 4) pri zdravljenju z bevacizumabom, v primerjavi z 1 primerom (stopnja 5) od 96 bolnikov (1 %), ki niso bili izpostavljeni bevacizumabu.
Before you are given MVASI or while you are being treated with MVASI: 
Preden začnete zdravljenje z zdravilom MVASI ali med zdravljenjem z njim:
In clinical trials, proteinuria has been reported within the range of 0.7% to 54.7% of patients receiving bevacizumab. 
V kliničnih preskušanjih so o proteinuriji poročali v obsegu od 0,7 do 54,7 % bolnikov, zdravljenih z bevacizumabom.
• Study E2100 (paclitaxel) Median PFS increase 5.6 months, HR 0.421 (p < 0.0001, 95% CI 0.343; 0.516) 
• študija E2100 (paklitaksel) mediana podaljšanja PFS 5,6 meseca, razmerje ogroženosti 0,421 (p < 0,0001, 95-% interval zaupanja 0,343; 0,516)
In the bevacizumab-containing arms, patients could receive bevacizumab as a single agent every 3 weeks until disease progression or unacceptable toxicity. 
V skupinah, ki sta prejemali bevacizumab, so bolniki lahko prejemali bevacizumab samostojno vsake 3 tedne do napredovanja bolezni ali do nesprejemljive toksičnosti.
MARKETING AUTHORISATION NUMBER(S) EU/1/17/1246/001 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/17/1246/001
MVASI is for intravenous use. 
Zdravilo MVASI je za intravensko uporabo.
• reduction in the number of white cells in the blood, and cells that help the blood clot, 
• zmanjšanje števila belih krvničk in celic, ki pomagajo strjevati kri,
However, somnolence and syncope have been reported with bevacizumab use (see table 1 in section 4.8). 
Vendar pa so pri uporabi bevacizumaba poročali o pojavu somnolence in sinkope (glejte preglednico 1 v poglavju 4.8).
Objective response rate1 
Objektivni odgovor1
A GOG PS of 2 at baseline was reported in 0.9% of patients in the CP arm and in 1.2% of patients in the CPB arm. 
O izhodiščnem stanju zmogljivosti po GOG 2 so poročali pri 0,9 % bolnic v skupini CP in pri 1,2 % bolnic v skupini CPB.
The risk of bevacizumab-associated hypertension did not correlate with the patients' baseline characteristics, underlying disease or concomitant therapy. 
Tveganje za pojav hipertenzije ob zdravljenju z bevacizumabom ni bilo povezano z osnovnimi značilnostmi bolnikov, spremljajočimi obolenji ali ostalo terapijo, ki so jo prejemali.
Eye disorders Eye disorder, Lacrimation increased 
Očesne bolezni bolezni oči, povečano solzenje
** Randomised patients with measurable disease at baseline. 
** Randomizirane bolnice, ki so izhodiščno imele merljivo bolezen.
Efficacy results from study GOG-0218 
Rezultati učinkovitosti iz študije GOG-0218
Randomised patients stage III optimally debulked disease2,3 
Randomizirane bolnice z optimalno citoredukcijo, stadija III2,3
Testing for proteinuria is recommended prior to start of MVASI therapy. 
Testiranje za proteinurijo je priporočljivo pred začetkom zdravljenja z zdravilom MVASI.
There have been rare reports of bevacizumab-treated patients developing signs and symptoms that are consistent with PRES, a rare neurologic disorder, which can present with the following signs and symptoms among others: seizures, headache, altered mental status, visual disturbance, or cortical blindness, with or without associated hypertension. 
Pri bolnikih, ki so se zdravili z bevacizumabom, so redko poročali o pojavu znakov in simptomov, povezanih s sindromom posteriorne reverzibilne encefalopatije (PRES, Posterior Reversible Encephalopathy Syndrome), redko nevrološko motnjo, ki se lahko kaže tudi z naslednjimi znaki in simptomi: epileptični napad, glavobol, spremenjeni mentalni status, motnje vida ali kortikalna slepota s sočasno hipertenzijo ali brez nje.
• allergic reactions (the signs may include difficulty breathing, facial redness, rash, low blood pressure or high blood pressure, low oxygen in your blood, chest pain, or nausea/vomiting), 
• alergijske reakcije (znaki lahko vključujejo težave pri dihanju; lahko se pojavi tudi rdečica obraza, izpuščaj, nizek ali visok krvni tlak, nizka raven kisika v vaši krvi, bolečina v prsnem košu ali slabost/bruhanje),
Severe adverse reactions by frequency 
Hudi neželeni učinki po pogostnosti
MARKETING AUTHORISATION NUMBER(S) EU/1/17/1246/002 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/17/1246/002
In study JO25567, all grade hypertension was observed in 77.3% of the patients who received bevacizumab in combination with erlotinib as first-line treatment for non-squamous NSCLC with EGFR activating mutations, compared to 14.3% of patients treated with erlotinib alone. 
V študiji JO25567 so hipertenzijo vseh stopenj opazili pri 77,3 % bolnikov, ki so prejemali bevacizumab v kombinaciji z erlotinibom v prvi liniji zdravljenja neskvamoznega nedrobnoceličnega raka pljuč z EGFR-aktivirajočimi mutacijami, v primerjavi s 14,3 % bolnikov, zdravljenih samo z erlotinibom.
At baseline, most patients in both treatment arms had a GOG PS of 0 (CP: 82.4%: CPB; 80.7%) or 1 (CP: 16.7%: CPB; 18.1%). 
Izhodiščno je imela večina bolnic v obeh zdravljenih skupinah stanje zmogljivosti po GOG (Gynecologic Oncology Group) 0 (CP: 82,4 %: CPB: 80,7 %) ali 1 (CP: 16,7 %, CPB; 18,1 %).
Clinical trials have shown that transient increases in serum creatinine (ranging between 1.5-1.9 times baseline level), both with and without proteinuria, are associated with the use of bevacizumab. 
Klinična preskušanja so pokazala, da so z bevacizumabom povezana prehodna zvišanja kreatinina v serumu (v razponu med 1,5 in 1,9-kratno izhodiščno vrednostjo) s proteinurijo ali brez nje.
• presence of protein in your urine accompanied by swelling of your body, 
• beljakovine v seču, ki jih spremlja otekanje telesa,
In study BO20924, bevacizumab exposure was generally lower compared to a typical adult patient at the same dose. 
V študiji BO20924 je bila izpostavljenost bevacizumabu v splošnem manjša kot pri tipičnem odraslem bolniku, ki je prejemal enak odmerek.
Cases of osteonecrosis of the jaw (ONJ) have been reported in patients treated with bevacizumab, most of which occurred in patients who had identified risk factors for ONJ, in particular exposure to intravenous bisphosphonates and/or a history of dental disease requiring invasive dental procedures (see also section 4.4) Cases of non-mandibular osteonecrosis have been observed in bevacizumab-treated paediatric patients (see section 4.8, Paediatric population) 
Bolezni mišično- skeletnega sistema in vezivnega tkiva pri bolnikih, zdravljenih z bevacizumabom, so poročali o primerih osteonekroze čeljustnic; v večini primerov je šlo za bolnike, pri katerih so bili prisotni znani dejavniki tveganja za osteonekrozo čeljustnic, zlasti izpostavljenost intravenskim difosfonatom in/ali anamneza zobne bolezni, ki je zahtevala invazivne zobozdravstvene posege (glejte tudi poglavje 4.4) pri zdravljenju pediatričnih bolnikov z bevacizumabom so opazili primere osteonekroze izven spodnje čeljustnice (glejte poglavje 4.8, Pediatrični bolniki)
Patients and percentage of patients with best overall response of confirmed CR or PR; percentage calculated on patients with measurable disease at baseline. 
Bolnice in odstotek bolnic z najboljšim celokupnim odgovorom, ocenjenim kot popolni odgovor ali delni odgovor, odstotek izračunan pri bolnicah z merljivo boleznijo ob izhodišču.
• The other ingredients are trehalose dihydrate, sodium phosphate, polysorbate 20 and water for injections. 
• Pomožne snovi so trehaloza dihidrat, natrijev fosfat, polisorbat 20 in voda za injekcije.
Decreased neutrophil count, decreased white blood cell count and presence of urine protein may be associated with MVASI treatment. 
Zmanjšanje števila nevtrofilcev, zmanjšanje števila levkocitov in prisotnost beljakovin v seču so lahko povezani z zdravljenjem z zdravilom MVASI.
In the absence of PD, discontinuation of one component of study treatment in the erlotinib + bevacizumab arm did not lead to discontinuation of the other component of study treatment as specified in the study protocol. 
V skupini, zdravljeni z erlotinibom in bevacizumabom, v odsotnosti napredovanja bolezni ukinitev enega od zdravil, uporabljenega v študiji, ni vodila do ukinitve drugega zdravila, kar je bilo v skladu s protokolom študije.
5.0 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks. 
5,0 mg/kg vsaka 2 tedna ali 7,5 mg/kg vsake 3 tedne.
Hypersensitivity reactions/infusion reactions (see section 4.4 and Post-marketing experience below) 
Preobčutljivostne reakcije/reakcije pri infundiranju (glejte poglavje 4.4 ter podnaslov Izkušnje po prihodu zdravila na trg, spodaj)
In four phase III trials (AVF2119g, E2100, BO17708 and AVF3694g) in patients with metastatic breast cancer CHF grade 3 (NCI-CTCAE v.3) or higher was reported in up to 3.5% of patients treated with bevacizumab in combination with chemotherapy compared with up to 0.9% in the control arms. 
V štirih preskušanjih faze III (AVF2119g, E2100, BO17708 in AVF3694g) so pri bolnikih z metastatskim rakom dojk o kongestivnem srčnem popuščanju stopnje 3 ali več (NCICTCAE v.3) poročali pri največ 3,5 % bolnikov, zdravljenih z bevacizumabom v kombinaciji s kemoterapijo, v primerjavi z največ 0,9 % bolnikov v kontrolnih skupinah.
• redness, peeling, tenderness, pain, or blistering on the fingers or feet, 
• rdečina, luščenje, občutljivost, bolečina ali pojav mehurjev na prstih ali nogah,
A total of 1,873 patients were randomised in equal proportions to the following three arms: 
Skupno je bilo randomiziranih 1.873 bolnic v enakem razmerju v naslednje tri skupine:
The primary endpoint of this trial was progression-free survival (PFS), based on trial investigators' assessment of disease progression. 
Primarni cilj tega preskušanja je bilo preživetje brez napredovanja bolezni (PFS), osnovano na oceni napredovanja bolezni s strani raziskovalcev.
If this happens you should talk to your doctor, pharmacist or nurse immediately. 
Če se to zgodi, se takoj posvetujte s svojim zdravnikom, farmacevtom ali medicinsko sestro.
• infections of the skin or deeper layers under the skin, 
• okužbe kože ali globljih plasti pod kožo,
How to use MVASI 
Kako uporabljati zdravilo MVASI
• runny nose, 
• izcedek iz nosu,
Bevacizumab may adversely affect the wound healing process. 
Bevacizumab lahko neugodno vpliva na proces celjenja ran.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 100 mg/4 mL 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 100 mg/4 ml
However, patients who developed venous thrombosis while receiving therapy did not appear to have an increased rate of grade 3 or above bleeding when treated with a full dose of warfarin and bevacizumab concomitantly (NCI-CTCAE v.3). 
Vendar bolniki, pri katerih se je med zdravljenjem pojavila venska tromboza, niso imeli povečane pojavosti krvavitev stopnje 3 ali več (NCI-CTCAE v.3), če so jih sočasno zdravili s polnim odmerkom varfarina in bevacizumabom.
Front-line treatment of ovarian cancer 
Prvo zdravljenje raka jajčnikov
Dose reduction of IFN alfa-2a did not appear to affect the efficacy of the combination of bevacizumab and IFN alfa-2a based on PFS event free rates over time, as shown by a subgroup analysis. 
Zmanjšanje odmerka interferona alfa-2a ni vplivalo na učinkovitost kombinacije bevacizumaba in interferona alfa-2a, kar je z deležem preživetja brez napredovanja bolezni v tem času potrdila analiza podskupine.
Caution should be exercised when treating patients with clinically significant cardiovascular disease such as pre-existing coronary artery disease, or congestive heart failure with bevacizumab. 
Pri zdravljenju z bevacizumabom je pri bolnikih s klinično pomembno kardiovaskularno boleznijo, kot je predhodno obstoječa bolezen koronarnih arterij ali kongestivno srčno popuščanje, potrebna previdnost.
• serious infections of the skin or deeper layers under the skin, 
• resne okužbe kože ali globljih plasti pod kožo,
The frequency of GI-vaginal fistulae in the group treated with bevacizumab + chemotherapy was higher in patients with recurrence within the field of prior radiation (16.7%) compared with patients with no prior radiation and/or no recurrence inside the field of prior radiation (3.6%). 
Pogostnost fistul med prebavili in nožnico v skupini, zdravljeni z bevacizumabom in kemoterapijo, je bila večja pri bolnicah s ponovitvijo bolezni v področju predhodnega obsevanja (16,7 %) v primerjavi z bolnicami brez predhodnega obsevanja in/ali brez ponovitve znotraj polja predhodnega obsevanja (3,6 %).
The primary efficacy endpoint was overall survival (OS). 
Primarni opazovani dogodek učinkovitosti je bil celokupno preživetje (OS, overall survival).
In patients in AVF3694g who received treatment with anthracyclines and who had not received anthracyclines before, no increased incidence of all grade CHF was observed in the anthracycline + bevacizumab group compared to the treatment with anthracyclines only. 
V preskušanju AVF3694g pri bolnikih, ki so prejemali zdravljenje z antraciklini in ki se predhodno še niso zdravili z antraciklini, niso opazili povečane incidence kongestivnega srčnega popuščanja katere koli stopnje v skupini z antraciklinom in bevacizumabom v primerjavi z zdravljenjem s samimi antraciklini.
Secondary endpoint Progression-free survival (PFS) 
Sekundarni opazovani dogodek Preživetje brez napredovanja bolezni (PFS)
Death of bone tissue (osteonecrosis) in bones other than the jaw have been reported in patients under 18 years old when treated with bevacizumab. 
O propadanju kostnega tkiva (osteonekrozi) v drugih kosteh, ne v čeljustnici, so poročali pri bolnikih, mlajših od 18 let, ko so se ti zdravili z bevacizumabom.
A third group of 110 patients received bolus 5-FU/FA + bevacizumab (Arm 3). 
Tretja skupina 110 bolnikov je prejela bolus 5-FU/FA + bevacizumab (skupina 3).
MVASI is for single-use only, as the product contains no preservatives. 
Zdravilo MVASI je le za enkratno uporabo in ne vsebuje konzervansov.
Proteinuriaa,b 
Bolezni sečil proteinurijaa,b
XELOX or 
XELOX ali
The most frequently observed adverse reactions across clinical trials in patients receiving bevacizumab were hypertension, fatigue or asthenia, diarrhoea and abdominal pain. 
Najpogostnejši neželeni učinki, ki so se pojavili pri bolnikih, zdravljenih z bevacizumabom v kliničnih preskušanjih, so bili hipertenzija, utrujenost ali astenija, diareja in bolečina v trebuhu.
A total of 1,528 patients were randomised in equal proportions to the following two arms: 
Skupno je bilo randomiziranih 1.528 bolnic v enakih razmerjih v naslednji dve skupini:
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 400 mg/16 mL 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 400 mg/16 ml
Pre-existing hypertension should be adequately controlled before starting MVASI treatment. 
Obstoječo hipertenzijo je treba pred začetkom zdravljenja z zdravilom MVASI ustrezno uravnati.
No clinically relevant interaction of bevacizumab was observed on the pharmacokinetics of co-administered interferon alfa 2a, erlotinib (and its active metabolite OSI-420), or the chemotherapies irinotecan (and its active metabolite SN38), capecitabine, oxaliplatin (as determined by measurement of free and total platinum), and cisplatin. 
Klinično pomembnega medsebojnega delovanja bevacizumaba na farmakokinetiko sočasno danega interferona alfa-2a, erlotiniba (in njegovega aktivnega presnovka OSI-420), kemoterapevtika irinotekana (in njegovega aktivnega presnovka SN38), kapecitabina, oksaliplatina (kot je dokazano z merjenjem proste in celokupne platine) in cisplatina niso opazili.
MVASI will be administered in combination with erlotinib. 
Zdravilo MVASI boste prejeli v kombinaciji z erlotinibom.
Treatment regimens in trial NO16966 (mCRC) 
Sheme zdravljenja v preskušanju NO16966 (metastatski rak debelega črevesa in danke)
Examples include palmar-plantar erythrodysaesthesia syndrome with pegylated liposomal doxorubicin or capecitabine, peripheral sensory neuropathy with paclitaxel or oxaliplatin, nail disorders or alopecia with paclitaxel and paronychia with erlotinib. 
Primeri vključujejo palmarno-plantarno eritrodisestezijo s pegiliranim liposomalnim doksorubicinom ali kapecitabinom, periferno senzorično nevropatijo s paklitakselom ali oksaliplatinom, bolezni nohtov ali alopecijo s paklitakselom in paronihijo z erlotinibom.
• Haemorrhage, including pulmonary haemorrhage/haemoptysis, which is more common in non small cell lung cancer patients (see section 4.4). 
• krvavitev, vključno s krvavitvijo v pljučih/hemoptizo, ki je pogostejša pri bolnikih z nedrobnoceličnim rakom pljuč (glejte poglavje 4.4),
MVASI will be administered in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy. 
Zdravilo MVASI se uporablja v kombinaciji s paklitakselom in cisplatinom ali, alternativno, s paklitakselom in topotekanom pri bolnicah, ki ne morejo dobivati zdravljenja s platino.
In clinical trials, with the exception of study JO25567, the overall incidence of hypertension (all grades) ranged up to 42.1% in the bevacizumab-containing arms compared with up to 14% in the control arms. 
V kliničnih preskušanjih, z izjemo študije JO25567, je bila celokupna incidenca hipertenzije (vseh stopenj) pri skupinah bolnikov, zdravljenih z bevacizumabom, do 42,1 % v primerjavi z do 14 % pri bolnikih, zdravljenih v primerjalnih skupinah.
Hazard ratio (95% CI) (registration form)b 
p-vrednost razmerje ogroženosti (95-% IZ) (registracijski obrazec)b
The European Medicines Agency has waived the obligation to submit the results of studies, in all subsets of the paediatric population, in breast carcinoma, adenocarcinoma of the colon and rectum, lung carcinoma (small cell and non-small cell carcinoma), kidney and renal pelvis carcinoma (excluding nephroblastoma, nephroblastomatosis, clear cell sarcoma, mesoblastic nephroma, renal medullary carcinoma and rhabdoid tumour of the kidney), ovarian carcinoma (excluding rhabdomyosarcoma and germ cell tumours), fallopian tube carcinoma (excluding rhabdomyosarcoma and germ cell tumours), peritoneal carcinoma (excluding blastomas and sarcomas) and cervix and corpus uteri carcinoma. 
Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij za vse skupine pediatrične populacije pri raku dojk, adenokarcinomu debelega črevesa in danke, raku pljuč (drobnoceličnem in nedrobnoceličnem), raku ledvic in ledvičnega meha (razen nefroblastoma, nefroblastomatoze, svetloceličnega sarkoma, mezoblastnega nefroma, raka ledvične sredice in rabdoidnega ledvičnega tumorja), raku jajčnikov (razen rabdomiosarkoma in germinalnih tumorjev), raku jajcevodov (razen rabdomiosarkoma in germinalnih tumorjev), primarnem peritonealnem karcinomu (razen blastoma in sarkoma) in raku materničnega vratu ter materničnega telesa.
The main secondary efficacy endpoint was progression-free survival (PFS). 
Glavni sekundarni opazovani dogodek učinkovitosti je bil preživetje brez napredovanja bolezni (PFS).
• MVASI may cause bleeding, especially tumour-related bleeding. 
• zdravilo MVASI lahko povzroči krvavitve, posebno krvavitve, povezane s tumorjem.
Grade 3 hypertension was 60.0% in patients treated with bevacizumab in combination with erlotinib compared to 11.7% in patients treated with erlotinib alone. 
Hipertenzijo stopnje 3 so opazili pri 60,0 % bolnikov, zdravljenih z bevacizumabom v kombinaciji z erlotinibom, v primerjavi z 11,7 % bolnikov, zdravljenih samo z erlotinibom.
Bevacizumab vs. No bevacizumab 
Bevacizumab proti brez bevacizumaba
• pain, including headache, back pain and pain in the pelvis and anal regions, 
• bolečino, vključno z glavobolom, bolečine v hrbtu in bolečine v predelu medenice in zadnjika,
The overall incidence of NCI-CTC grade 3 and 4 hypertension in patients receiving bevacizumab ranged from 0.4% to 17.9%. 
Celokupna incidenca hipertenzije stopnje 3 in 4 po NCI-CTC je bila pri bolnikih, ki so se zdravili z bevacizumabom, od 0,4 do 17,9 %.
The 649 randomised patients (641 treated) had Karnofsky Performance Status (KPS) of ≥ 70%, no CNS metastases and adequate organ function. 
V klinično preskušanje je bilo randomiziranih 649 bolnikov (641 pa zdravljenih), njihovo stanje zmogljivosti po Karnofskem je bilo ≥ 70 %, bili so brez zasevkov v osrednjem živčevju, imeli so ustrezno organsko funkcijo.